Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo continues to deliver impressive sales despite increased competition, but uncertainties about the all-important CheckMate 227 study of combination use with Yervoy in first-line non-small cell lung cancer, including the relevance of tumor mutation burden as an emerging immuno-oncology biomarker, cast a bit of a cloud on the third quarter.
Bristol reported sales of about $1.3bn for Opdivo (nivolumab) for the third quarter, up 38% from the same period in 2016
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?